Hybridoma Technology for Antibody Discovery
Antibody Discovery Services
Hybridoma Technology for Antibody Discovery Overview
Hybridoma technology stands as the most mature and widely utilized method for antibody discovery today. This approach involves fusing immunized mouse spleen cells with myeloma cells, resulting in the selection of hybridoma cell lines capable of secreting target antibodies. Subsequently, the target antibodies are obtained through sequencing and expression within a eukaryotic system.
Our company offers a comprehensive research and development pathway encompassing antigen preparation, animal immunization, antibody screening, and quality control analysis. We have the capability to design personalized screening plans tailored to the specific needs of our customers, ensuring we fully meet the requirements for obtaining the target antibody.
All Antibody Discovery Services
Hybridoma technology is the bedrock of antibody discovery, merging immunized cells to generate monoclonal antibodies. This ensures consistency, high specificity, and high yield for therapeutic and diagnostic applications.
Single B cell screening represents a breakthrough in antibody discovery. Using state-of-the-art technology to isolate, sequence, and analyze individual B cells, ensuring precise identification of specific antibodies for novel treatments.
Utilizing advanced biotechnology, our engineered bispecific antibodies bind two distinct targets. This innovation has the potential to revolutionize therapeutic strategies, heightening specificity, expanding treatment options, and paving the way for future medical advancements.